Akeso Inc. rebound has not surpassed 138.7. Retail investors should distinguish between a rebound and a true strengthening before entering.

The closing price the previous day (6th) was 133.500, and the short-term trend has not truly strengthened yet. Although the share price rebounded on the latest trading day with higher trading volume compared to the previous day, indicating buying support at lower levels, the price remains below the 10-day moving average of 134.610 and the middle Bollinger Band line of 138.700. This suggests that the current rebound is merely a reaction after a pullback from higher levels, failing to confirm a return to a strong uptrend.

Looking at the biopharmaceutical sector, most stocks (including Akeso Inc. (09926), $CANSINOBIO (06185.HK)$ 、 $JUNSHI BIO (01877.HK)$ 、 $WUXI BIO (02269.HK)$) have technical signals showing 'Buy', and their RSI values are generally below 50, indicating that the sector as a whole is in a recovery window following short-term oversold conditions.

Notably, although the technical outlook for peers is mostly bullish, $INNOVENT BIO (01801.HK)$ The technical signal, however, is showing 'sell,' highlighting internal divergence within the sector. This indicates that Akeso's rebound is occurring in an environment where the sector as a whole has technical rebound needs but consensus on capital flow has not been fully reached. Its 'buy' signal provides some sectoral support for its rebound, but it failed to break through key moving averages, suggesting its rebound momentum lags behind others in the sector. This means that for it to shift from a rebound to strengthening, it not only needs the sector to recover but also must demonstrate individual stock momentum that surpasses its peers.

Akeso’s first critical level right now is 134.610. If the stock price can rise above this level again, the short-term rebound will be considered preliminarily improved, and then we can look towards 138.700 next. The real watershed lies at 138.700; only by breaking through and stabilizing above this level can we say that Akeso has transitioned from a pullback to regaining strength. If it fails to regain 134.610, the rebound momentum remains insufficient, and 124.587 will still be an important support level that needs to hold.

The Relative Strength Index (RSI) is around 46.940, still below the neutral-to-strong level, indicating that momentum has not fully recovered. This is crucial because Akeso Inc. has experienced high volatility in the past, and investors may mistakenly believe the downtrend has ended due to a single-day rebound. However, based on the current technical situation, the share price still requires a confirmed breakout. At this stage, the risk-reward ratio is only moderate, making it unsuitable to chase the stock using a strong uptrend logic.

Among investor comments, bullish voices are mainly concentrated on phrases like 'good performance today,' '135 tomorrow,' 'buy the dip,' and 'a good opportunity to enter.' These opinions reflect that the market is still willing to look for opportunities to buy on dips during Akeso Inc.'s pullbacks. This is not entirely without merit, as the share price remains above 124.587, with no breakdown below that level, and the rebound is supported by trading volume. However, the issue is that near 133.500, which is close to 134.610, failure to break through in the short term could lead to pressure when chasing the stock.

A more reasonable way to be bullish is to wait for the stock price to first rise above 134.610, then observe whether it can challenge 138.700, instead of immediately concluding a renewed strengthening at the first sign of a rebound. As for the approach of 'buying every dip,' this only works if the broader range remains intact. Once the price falls below 124.587, this logic of buying on dips will fail.

Bearish comments clearly carry a sense of defeat, such as 'it will definitely fall,' 'beaten to a pulp,' or 'only know how to jump off a building.' These comments reflect that many investors have already lost confidence due to the recent pullback from higher levels. However, directly concluding a certain decline at this stage may not be rigorous enough, as the latest rebound has trading volume support, and the stock price has not yet fallen below 124.587. A true weakening would require seeing the stock price fail to rebound and then drop towards 124.587 again, or even break below that level.

The most noteworthy are the观望 (wait-and-see) comments. 'Starting to buy puts at 134.5' is actually very close to the short-term resistance level since 134.610 is indeed the first resistance. If the stock price is noticeably rejected near 134.610, shorting in the short term would have some technical basis; but if the stock price breaks through 134.610 and continues toward 138.700, shorting too early could easily result in being squeezed by the rebound. 'Fluctuating between 110 and 140' reflects the market's view that Akeso is still within a broad range, consistent with the current technical state, as the stock price hasn't broken above 138.700 and remains in a range-bound pattern.

Overall, Akeso Biologics is not so weak that it should be avoided entirely, but it has not yet regained strength either. The short-term trading framework is clear: breaking back above 134.610 would improve the rebound; surpassing 138.700 would indicate structural strengthening; while dropping toward 124.587 would require retesting support. Those without positions should avoid chasing aggressively before a breakout, while those holding positions should pay attention to whether 134.610 and 138.700 can be reclaimed step by step.

The core issue for Akeso Biologics now is not whether there will be a rebound, but whether the rebound can turn into a sustained strengthening. On one hand, some in the market want to jump in long, while others want to go short, reflecting that the stock price is in an awkward position. The real answer does not lie in sentiment but in whether the stock can decisively break through the two key levels: 134.610 and 138.700.

Reply to some investors' views:

@價值投資同行者: Pullbacks for bargain hunting are acceptable, but 124.587 must hold. If it breaks below this level, the rationale for buying on dips would deteriorate.

@打新小超人: You can wait for confirmation before entering. Before the current price rises back above 134.610, the risk-reward ratio is only neutral.

@勤力的小文子: Bearish views require technical confirmation. Unless it falls below 124.587, we cannot definitively say it will drop.

Based on the above analysis, the strategies for deployment can be divided into the following main approaches:

Key Deployment: Current price is below both 134.610 and 138.700. In the short term, focus on whether it can rise back above 134.610. After stabilizing, you can test 138.700. Breaking through 138.700 can be seen as an improvement in the rebound. If 134.610 fails to hold, be prepared for a retreat to 124.587.

Strategy One | Test 138.700 after reclaiming 134.610
$UBAKESO@EC2608A.C (25944.HK)$ | Strike Price 131.36 | Actual Leverage 3.3x | Close to current price and slightly in-the-money, suitable for the early stage of a rebound. While not the most aggressive option, it is better suited for waiting until the stock price stabilizes before following up.
$BIAKESO@EC2608A.C (25994.HK)$ | Strike Price 131.36 | Actual Leverage 3.5x | Also close to the current price, with higher leverage. Suitable for those optimistic about testing 134.610 and pursuing a short-term rebound afterward, though it shouldn’t be held for too long.
$HSAKESO@EC2608A.C (25962.HK)$ | Strike Price 131.36 | Actual Leverage 3.4x | A near-price rebound tool, ideal for participating when the stock transitions from weakness to stability. The key is to wait for stabilization above 134.610.

Strategy Two | Improved rebound chase after breaking through 138.700
$BPAKESO@EC2610A.C (27059.HK)$ | Strike price 138.88 | Actual leverage 2.8x | Strike price close to the 138.700 resistance, suitable for use after a breakout confirmation, primarily targeting extended upside after the breakout.
$HUAKESO@EC2608A.C (26813.HK)$ | Strike price 131.36 | Actual leverage 3.4x | Closer to the current price, suitable for trend-following deployment that retains some stability post-breakout; not the most explosive but easier to align with the underlying stock.
$UBAKESO@EC2608A.C (25944.HK)$ | Strike price 131.36 | Actual leverage 3.3x | Suitable for relatively stable follow-up after a breakout; if the stock price breaks through 138.700 but doesn’t surge too quickly, it serves as a medium-to-low leverage trend-following option.

For more market analysis, stay tuned to Jenny's daily updates on 'Hong Kong Stock Warrants'!

Reminder: This article does not constitute any investment advice.

This article is for reference only and does not constitute any investment advice. Market data, opinions, and analysis contained herein may change at any time without prior notice. We are not responsible for any loss or damage caused by reliance on the information in this article. Technical analysis only shows whether certain technical conditions are met; asset performance should be comprehensively evaluated using other sources of information, and trading decisions should not be made solely based on this article. Please note that past performance is not indicative of future results.

#HKStocks #CansinoBiologics #Real-TimeAnalysis #WarrantPick #WarrantGuide #DerivativesHedging #HKWarrantsJenny #Blue-ChipStocks #TechnicalAnalysis

$Hang Seng Index (800000.HK)$ $Hang Seng China Enterprises Index (800100.HK)$ $Hang Seng TECH Index (800700.HK)$

228K Views